TET2 and cancer: Similarly, whereas mice deficient in Tet2 alone develop myeloid and occasionally lymphoid malignancies with long latency, succumbing by ~400 days32–34, mice with double deficiency of Tet2 and Tet3 in T, B, and myeloid cells develop aggressive cancers.